Over the last year, the European Commission (EC) has been consulting on multiple scenarios for HTA h...
Read moreThe development of gene therapies represents a new frontier of science, with the potential to help p...
Read moreWe are delighted to say that we have received a fabulous response, with 32 responses from at least 1...
Read moreSince 2004, opportunity cost has been reflected in NICE's appraisal process through the specificatio...
Read moreRemap Consulting are proud to announce that we are hosting two, 1 day market access training worksho...
Read moreThis study investigates NICE evaluations of new cancer indications and legacy CDF indications (not p...
Read morePaul Craddy is proud to be presenting at the Global Pharmaceutical Regulatory Affairs Summit in Prag...
Read moreThe Association of British Pharmaceutical Industry has been refused a legal challenge to a cap on th...
Read moreOur training courses are designed to help your organization to understand market access and what it ...
Read moreObtaining market access at the right time and at an appropriate price has become more complex for ph...
Read more